The earnings call highlighted significant growth in VYVGART sales and strong financial performance, demonstrating market expansion and successful product launches. However, challenges such as increased operating expenses and gross to net adjustments were noted. The overall sentiment is positive due to the substantial growth and strategic advancements outweighing the challenges.

Company Guidance

During the call, Argenx provided comprehensive guidance on its financial and strategic outlook, marked by significant growth metrics. The company reported a total operating income of $967 million for the second quarter of 2025, a 97% increase year-over-year, largely driven by $949 million in product net sales and $19 million in other operating income. VYVGART's global reach expanded to 15,000 patients, including 2,500 CIDP patients within the first year of launch, highlighting a 97% year-over-year growth. The U.S. market contributed $802 million, Japan $52 million, and other regions $83 million, with $12 million from product supply to Zai Lab in China. The gross margin remained steady at 11%, with operating expenses totaling $766 million. Argenx's pipeline continues to advance, with three Phase III assets in development, aiming to reach 50,000 patients by 2030. The company maintains a robust cash balance of $3.9 billion, supporting its commitment to innovation and strategic growth across various therapeutic areas.

Exceptional Growth in VYVGART

VYVGART achieved exceptional year-over-year growth of 97% across all approved indications. 15,000 patients globally are now being treated, including 2,500 CIDP patients within one year of launch.

Strong Financial Performance

Total operating income in Q2 2025 was $967 million, with $949 million in product net sales, representing a 97% growth since last year. Operating profit for the period was $201 million.

Expansion into New Markets

Initiated multiple registrational trials in large market opportunities like Sjögren's, myositis, and TED, and advanced 4 new molecules into the pipeline.

Commercial Success with Prefilled Syringe

The prefilled syringe is driving new patient starts and prescriber demand. Over 1,000 physicians have prescribed it, with 15% being first-time prescribers.

Strong International Growth

All global markets grew in the second quarter, with the U.S. delivering 18% quarter-over-quarter growth. The overall contribution of non-U.S. regions now represents more than 15% of global product net sales.

arGEN X (GB:0QW0) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

GB:0QW0 Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 30, 2025	2025 (Q3)	3.86 / -	1.28	―	―	―
Jul 31, 2025	2025 (Q2)	2.64 / 3.27	0.415	687.47% (+2.85)	―	―
May 08, 2025	2025 (Q1)	2.15 / 2.29	-0.965	337.10% (+3.25)	―	―
Feb 27, 2025	2024 (Q4)	1.65 / 11.32	-1.552	829.51% (+12.87)	―	―
Oct 31, 2024	2024 (Q3)	0.13 / 1.28	-1.183	208.20% (+2.46)	―	―
Jul 25, 2024	2024 (Q2)	-0.83 / 0.41	-1.538	126.98% (+1.95)	―	―
May 09, 2024	2024 (Q1)	-0.72 / -0.96	-0.473	-104.02% (-0.49)	―	―
Feb 29, 2024	2023 (Q4)	-1.19 / -1.55	-0.66	-135.15% (-0.89)	―	―
Oct 31, 2023	2023 (Q3)	-1.35 / -1.18	-4.261	72.24% (+3.08)	―	―
Jul 27, 2023	2023 (Q2)	-1.53 / -1.54	-3.752	59.01% (+2.21)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

GB:0QW0 Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 31, 2025	€518.28	€593.70	+14.55%
May 08, 2025	€549.35	€488.35	-11.10%
Feb 27, 2025	€598.91	€609.95	+1.84%
Oct 31, 2024	€513.16	€529.63	+3.21%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does arGEN-X SE (GB:0QW0) report earnings?

arGEN-X SE (GB:0QW0) is schdueled to report earning on Oct 30, 2025, TBA (Confirmed).

What is arGEN-X SE (GB:0QW0) earnings time?

arGEN-X SE (GB:0QW0) earnings time is at Oct 30, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is the P/E ratio of arGEN-X SE stock?

The P/E ratio of arGEN X is N/A.

What is GB:0QW0 EPS forecast?

GB:0QW0 EPS forecast for the fiscal quarter 2025 (Q3) is 3.86.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing